ArticleJournal of oral rehabilitation2026
Impact of TCAs and Gabapentin on Saliva and BMI in Adults With Xerostomia.
Article in Journal of oral rehabilitation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundTricyclic antidepressants (TCAs) and gabapentin are commonly associated with xerostomia and weight gain, a pattern that remains underexplored in the context of comorbidities and demographic variables in real-world observational samples.
objectivesTo evaluate the associations of TCA and gabapentin use with body mass index (BMI) and a comprehensive panel of oral dryness outcomes, and to examine the influence of demographic and clinical variables on these measures.
methodsThis study included 147 adults aged 45-64 years with medication-related xerostomia. Oral dryness was assessed using unstimulated whole saliva (UWS), minor salivary flow (MSF) and the Xerostomia Inventory (XI). Data on medication exposure, anticholinergic burden, BMI and comorbidities were obtained from electronic records and standardized questionnaires. Associations were tested using multivariable linear regression models.
resultsUse of TCAs or gabapentin was not independently associated with BMI or oral dryness after adjustment for comorbidities. Female sex, greater anticholinergic burden and conditions such as gastroesophageal reflux, obstructive sleep apnea and thyroid disease showed stronger associations with reduced salivary flow (< 0.30 mL/min) and higher XI scores. Race and depression were also independently related to BMI and XI scores.
conclusionOral dryness (< 0.30 mL/min) and BMI outcomes in medication-related xerostomia were more strongly associated with demographic and clinical variables than with the utilization of TCAs or gabapentin. These findings underscore the importance of conducting longitudinal research to investigate the temporal and contextual relationships between BMI, salivary measures and xerostomia in real-world clinical populations. However, a medication-matched control group without xerostomia was not included, which limits the interpretation of the results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.